Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Abeona Therapeutics (ABEO) Asset Writedowns and Impairment (2022)

Abeona Therapeutics has reported Asset Writedowns and Impairment over the past 1 years, most recently at $192000.0 for Q4 2022.

Quarterly results put Asset Writedowns and Impairment at $192000.0 for Q4 2022, changed N/A from a year ago — trailing twelve months through Dec 2023 was $231000.0 (down 87.11% YoY), and the annual figure for FY2023 was -$1.1 million, down 159.43%.
Asset Writedowns and Impairment for Q4 2022 was $192000.0 at Abeona Therapeutics, up from $39000.0 in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for ABEO hit a ceiling of $1.4 million in Q1 2022 and a floor of $39000.0 in Q3 2022.